^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ASKG915

    i
    Other names: ASKG915, ASKG-915, ASKG 915
    Associations

    News

    Trials
    Company:
    Aosaikang Pharma
    Drug class:
    PD1 inhibitor, IL-15R agonist
    Related drugs:
    Associations

    News

    Trials
    10d
    A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=594, Recruiting, AskGene Pharma, Inc. | Phase classification: P1 --> P1/2 | N=104 --> 594 | Trial completion date: Dec 2025 --> Jun 2028 | Trial primary completion date: Mar 2024 --> Dec 2026
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • paclitaxel • docetaxel • Fruzaqla (fruquintinib) • ASKG915
    over2years
    A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=104, Not yet recruiting, AskGene Pharma, Inc.
    New P1 trial • Metastases
    |
    ASKG915